Searching happens on your device — what you type here never leaves your browser.

skin-care 9 min read · August 25, 2026

Hormone Therapy and Black Skin

Part 3 — What the Evidence Says for Us

In this series: Part 1: What's Normal and What's Not | Part 2: Hair Changes in Peri/Menopause | Part 3: Hormone Therapy and Black Skin | Part 4: When to Worry

If you're considering hormone therapy for menopause symptoms, you may also be wondering what it could mean for your skin. Could it help the dryness or loss of firmness you've noticed? Could estrogen make melasma or dark patches worse? Could it help thinning hair? And how much of what we know was actually studied in Black women?

The 3 Things We Should Know

Menopausal hormone therapy (MHT) can affect your skin, but skin benefits should not be the reason you start it.

MHT may improve dryness, hydration, collagen, and firmness, but Black-specific evidence is limited.

Estrogen can also affect pigmentation, so if you are prone to melasma or dark patches, that belongs in the conversation before you start.

Menopausal hormone therapy, often shortened to MHT (the medical term for what used to be called HRT, or hormone replacement therapy), is the most effective treatment we have for hot flashes and night sweats, and it also helps protect the bone mass we lose after menopause.1-3 It has real effects on the skin too — better collagen, better hydration, fewer wrinkles, and in some studies, slower facial skin aging.4-8

Here is a hard truth: even though Black women have longer hot flashes than any other group studied,9 we are less likely to be offered or prescribed MHT.10,11

MHT is prescribed primarily to treat menopause symptoms, not skin aging. Whether MHT is appropriate for you depends on your symptoms, age, medical history, medications, and individual risks. That decision belongs with your gynecologist or other clinician managing your menopause care. Here, we focus on a different question: what should Black women know about how hormone therapy may affect our skin and hair?

That gap is part of what this article is about. The other part is the science, i.e., what MHT does, and does not do, for your skin and hair, and what to ask before you start.

This is Part 3 of the WeSeeColor Perimenopause/Menopause series. If you haven't read Part 1: What's Normal and What's Not or Part 2: Hair Changes in Peri/Menopause, you can find both linked above.

The Disparity

A 2022 study of nearly 200,000 women veterans, most in their late 40s through mid-60s, found that Black women had lower odds of having menopause symptoms documented in their medical records, even after researchers adjusted for symptoms, age, weight, and depression. We also had lower odds of being prescribed hormone therapy.10 A 2025 review that looked across many studies and care settings reached the same conclusion: documented and prescribed MHT is consistently lower for Black women than for White women, even when symptoms are similar.11 To put a number on it, in the veterans' study above, Black women had about 18% lower odds of having a menopause diagnosis in their chart, and about 26% lower odds of being prescribed hormone therapy.10 Knowing this can change the conversation you walk into.

Black women are also consistently less likely to use or accept MHT, even when we have symptoms.10,12,13 The reasons are not simply personal choice. They likely include different treatment preferences, differences in how counseling happens in the exam room, and unequal access to care or documentation of symptoms.10,13,14 Structural racism in health care has been identified as a real contributor to both symptom burden and treatment barriers, and researchers who study these gaps argue that the layered effects of racism, discrimination, and implicit bias help explain why our menopause symptoms are so often more severe and less treated.15 This is exactly why finding a doctor who understands our health history and takes our symptoms seriously matters so much.

Why the Research Gap Matters to You

Here is something every Black woman should know before reading further: most of the large hormone therapy trials did not include many of us. In the Women's Health Initiative (WHI), only about 8.9% of the nearly 162,000 participants were Black women.16 In the Kronos Early Estrogen Prevention Study (KEEPS), only 7% of the 728 women in the trial identified as Black.17 One important exception: a separate WHI trial that studied estrogen-alone therapy enrolled 1,616 Black women out of 10,739 participants, about 15%, which gives us more solid data from that specific trial.18

MHT works well for hot flashes and night sweats, and it offers modest help for skin. But the exact size of those benefits and risks for Black women specifically has not been well studied. As you'll see below, the one large trial that did look separately at Black women's skin, KEEPS, found real differences from White women.17,19 That is not a reason to avoid MHT. It is a reason to insist on shared decision-making with a doctor who understands this history, rather than accepting a blanket yes or no. Here is what you should know when making decisions about your skin and hair.

What Changes in Our Skin as Estrogen Falls?

Estrogen receptors sit throughout your skin, on the cells that build collagen and elastin, on oil glands, and on hair follicles. Perimenopause often starts with hormone levels swinging up and down rather than steadily falling, so oil production can vary early on, before the more constant estrogen drop of full menopause brings the dryness and itch that so many women notice later.20 After menopause, once estrogen stays low, skin loses about 30% of its collagen in the first five years and roughly 2% a year after that.4-6

It's worth noting that this collagen research comes from studies of women in general, not research that separately measured Black women. What we do know, from the KEEPS trial discussed below, is that Black women tend to start the menopause transition with fewer visible wrinkles, which suggests our skin does not always age the same way as the skin studied in most of this research.19 That is one more reason the sagging and firmness changes described next may matter more for us than fine lines do.

What Can MHT Actually Do for Your Skin?

The encouraging part is that therapy can help rebuild some of what menopause takes away. Research shows it can:

Increase collagen and skin thickness in postmenopausal women who use estrogen, especially when they start early in menopause.4-6,21

Improve skin hydration, elasticity, and barrier function, meaning less of the dryness and itch that bother so many menopausal women.6,8,22

Help wounds heal better, a benefit that gets less attention than it deserves.5

Reduce fine wrinkles, although the four-year KEEPS trial found that race was a stronger predictor of skin aging than which treatment group a woman was in. Black women in the trial started with fewer wrinkles than White women and ended with fewer wrinkles too, no matter which treatment arm they were on.19,21

What the KEEPS Trial Really Means for Black Skin

KEEPS is the only large randomized trial that measured skin in different racial groups during the menopause transition, and its finding for Black women is specific. Over four years, Black women lost meaningful firmness, or what researchers call rigidity, in their facial skin, but had significantly fewer wrinkles than White women in every treatment group, whether they took hormones or not.19

Here is the translation. If your top skin complaint is sagging or a jawline that feels softer than it used to, hormone therapy is a more plausible source of help than if your top complaint is fine lines. That fits what many of us already notice; we tend to see less visible wrinkling, but firmness and elasticity still shift. It's also worth remembering that the evidence for hot flashes, sleep, mood, and bone health is much stronger than the evidence for any single skin benefit. Don't choose hormone therapy for your skin alone.

Will MHT Help the Skin Change I Am Worried About?

Some of what follows applies to all women going through menopause. A few rows matter more, or differently, for Black skin specifically, especially melasma and dark patches, covered in its own section below.

  • Dryness or itching — May help.6,22
  • Loss of firmness — Possibly, especially if started early in menopause.4,19
  • Fine lines — Some evidence it helps, but probably less important for many Black women, since we tend to have fewer visible wrinkles to begin with.19
  • Melasma or dark patches — May worsen with systemic estrogen. See the next section.
  • Adult acne or new chin hairs — Mixed picture; effects are hard to predict.8,23
  • Hair thinning — Don't assume MHT will treat it. See "What About My Hair?" below.

Adult acne or new chin hairs: The effect of MHT is less predictable. If these changes are bothering you, don't assume changing your hormone therapy is the answer. Ask your dermatologist whether the changes are hormonal and whether they need separate treatment.23,24 For additional information, see Part 4 in this series: When Menopause Skin or Hair Changes May Signal a Medical Problem at WeSeeColor.net.

Could Hormone Therapy Make My Dark Patches Worse?

Melasma and other dark patches deserve their own conversation, because they sit right at the intersection of Black skin and hormone therapy. Systemic estrogen, meaning a pill, patch, gel, or spray that raises estrogen throughout your body, can worsen melasma the same way combined birth control pills or pregnancy can.23 Topical or vaginal estrogen has much less effect on pigment.25,26

If you already have melasma or have experienced hormone-related pigmentation changes before, make that part of the conversation before starting MHT. Daily sun and visible-light protection is especially important, and your dermatologist can help you decide whether your pigmentation routine should change, such as committing to using a daily mineral sunscreen with iron oxide or adding azelaic acid.25-28

I'm Seeing Estrogen Face Creams Online. Should I Try One?

You may have seen compounded estrogen face creams marketed for anti-aging, usually made with estradiol or estriol, two forms of estrogen. Small studies show these can improve skin thickness, hydration, and elasticity.6,8,29 But these creams are off-label, meaning the FDA has not specifically approved them for this use, and the hormone in them can be absorbed into your bloodstream, not just your skin. Don't start one without your doctor's input, especially if you have a history of an estrogen-sensitive cancer, and know that compounded versions are custom-mixed by a pharmacy and are not tested and regulated the same way an FDA-approved product is.30

WeSeeColor® Takeaway

Don't assume an "estrogen face cream" is just another anti-aging cosmetic. If a product contains a hormone or hormone-like ingredient, ask your clinician what it is, whether it can be absorbed beyond the skin, and whether it is appropriate for you before using it. Your dermatologist may mention MEP (methyl estradiolpropanoate), a topical ingredient that engages estrogen receptors in the skin.7,8

What About My Hair?

MHT is not a hair-loss treatment. If you're noticing crown thinning, recession, scalp symptoms, or breakage, don't assume replacing estrogen will fix it. The first step is determining what type of hair loss you have. See Part 2: Hair Changes in Peri/Menopause for what to look for, when to see a dermatologist, and what treatment options may be discussed.

Is MHT Safe?

The Women's Health Initiative results from the early 2000s scared a generation of doctors and patients away from MHT. An 18-year follow-up, published in JAMA in 2017, told a more nuanced story: no significant increase in all-cause mortality with combined or estrogen-alone therapy, and lower mortality in women who started MHT between ages 50 and 59 or within 10 years of menopause.31 The risk-benefit balance shifts as women age and as time since menopause grows. For women who start hormone therapy more than 10 years after menopause, or who are older than 60, the benefits versus the risks look less favorable because of greater risks of heart disease, stroke, blood clots, and dementia. Discuss your full medical history with your doctor if you're considering MHT; there may be safer alternatives depending on your history.2

MHT has benefits and risks that depend on your age, symptoms, medical history, medications, and other factors. Deciding whether MHT is appropriate for you belongs with the clinician managing your menopause care.2,8 From a WeSeeColor® perspective, there is another question to add to that conversation: What might this treatment mean for my skin, pigmentation, and hair?

If You Are Considering MHT, Ask About Your Skin Too

When you talk with your gynecologist or menopause clinician about whether MHT is right for you, bring your skin and hair into that conversation too. If your gynecologist cannot address your concerns or does not have experience with Black skin, see a dermatologist with this experience.

Four questions worth asking:

  1. "Could this form of hormone therapy worsen my melasma or other pigment changes?"
  2. "Which of the skin changes I'm experiencing might realistically improve with MHT, and which probably won't?"
  3. "If my skin or hair changes after I start MHT, how will we know whether the hormones are responsible?"
  4. "Should I talk with my dermatologist about my skincare routine or pigmentation before I start?"

What You Can Do for Your Skin Whether You Choose MHT or Not

MHT is not your skincare routine. Whether you use hormone therapy or not, you can still address dryness, dark marks, acne, and visible skin aging directly.

Non-prescription approaches

If dryness is bothering you: focus on gentle cleansing and a barrier-supporting moisturizer.

If dark marks or melasma are your concern: daily sun protection, including protection from visible light, matters.25-27 Ask your dermatologist what else makes sense for your pigmentation.

If acne is your concern: don't assume MHT will solve it. Ask whether your acne needs its own treatment plan.24

If visible skin aging is your concern: ask your dermatologist which evidence-based topical options fit your skin and tolerance.

Before adding something new: check WeSeeColor® Community Products or submit the product to WeSeeColor® for evaluation.

The WeSeeColor Bottom Line

Hormone therapy can affect your skin, but don't start MHT to treat skin aging alone. It may improve dryness, hydration, collagen, and firmness, but the evidence specifically in Black women is limited, and estrogen can sometimes worsen melasma and dark patches. If you're considering MHT for menopause symptoms, make your skin part of the conversation. Tell your clinician about pigment changes, acne, hair changes, and the products you use, and ask which changes MHT may realistically help, which it may worsen, and which need a dermatologist instead.

Considering a product for dryness, dark marks, acne, or other skin changes during perimenopause or menopause? Start with the concern you are trying to address, not the claim on the package. Submit the product to WeSeeColor® for an evaluation to better understand what it is designed to do, what the evidence says, and whether it makes sense for your specific skin concern.

Where to Go Next in This Series

All four parts of this series:

Part 1: What's Normal and What's Not. The overview.

Part 2: Hair Changes in Peri/Menopause. CCCA, FPHL, FFA, and breakage.

Part 4: When Menopause Skin or Hair Changes May Signal a Medical Problem. The red flags that need a doctor, not a routine.

This article is for education and is not medical advice. Decisions about menopausal hormone therapy should be made with a clinician who knows you. Read the full WeSeeColor Perimenopause/Menopause series and submit a product for review.

References

  1. Pan M, Pan X, Zhou J, Wang J, Qi Q, Wang L. Update on hormone therapy for the management of postmenopausal women. Biosci Trends 2022;16(1):46-57. DOI: 10.5582/bst.2021.01418.
  2. The 2022 hormone therapy position statement of The North American Menopause Society Advisory Panel. Menopause 2022;29(7):767-94. DOI: 10.1097/GME.0000000000002028.
  3. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015;100(11):3975-4011. DOI: 10.1210/jc.2015-2236.
  4. Brincat M, Versi E, Moniz CF, Magos A, de Trafford J, Studd JW. Skin collagen changes in postmenopausal women receiving different regimens of estrogen therapy. Obstet Gynecol 1987;70(1):123-7. PMID: 3601260.
  5. Wilkinson HN, Hardman MJ. The role of estrogen in cutaneous ageing and repair. Maturitas 2017;103:60-4. DOI: 10.1016/j.maturitas.2017.06.026.
  6. Rzepecki AK, Murase JE, Juran R, Fabi SG, McLellan BN. Estrogen-deficient skin: the role of topical therapy. Int J Womens Dermatol 2019;5(2):85-90. DOI: 10.1016/j.ijwd.2019.01.001.
  7. Draelos ZD. A double-blind, randomized pilot study evaluating the safety and efficacy of topical MEP in the facial appearance improvement of estrogen-deficient females. J Drugs Dermatol 2018;17(11):1186-9.
  8. Lephart ED. Bioactives for estrogen-deficient skin: topical and oral supplement clinical studies. A narrative review. Dermatol Ther (Heidelb) 2025;15(7):1681-703. DOI: 10.1007/s13555-025-01413-2.
  9. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015;175(4):531-9. DOI: 10.1001/jamainternmed.2014.8063.
  10. Blanken A, Gibson CJ, Li Y, et al. Racial/ethnic disparities in the diagnosis and management of menopause symptoms among midlife women veterans. Menopause 2022;29(7):877-82. DOI: 10.1097/GME.0000000000001978.
  11. Conklin D, Ramakrishnan A, Yu L, et al. Health disparities and hormone therapy prescribing for early, peri-, and postmenopausal women: a scoping review. J Racial Ethn Health Disparities 2025;12(6):4151-72. DOI: 10.1007/s40615-024-02209-4.
  12. Yang L, Toriola AT. Menopausal hormone therapy use among postmenopausal women. JAMA Health Forum 2024;5(9):e243128. DOI: 10.1001/jamahealthforum.2024.3128.
  13. Pershad A, Morris J, Khanna P. Racial and ethnic disparities in menopausal hormone therapy acceptance [A134]. Obstet Gynecol 2022;139(Suppl 1):39S. DOI: 10.1097/01.AOG.0000825816.61927.41.
  14. Christmas M, Janssen I, Joffe H, Upchurch D, Santoro N, Kravitz HM. Menopause hormone therapy and complementary alternative medicine, quality of life, and racial/ethnic differences: the Study of Women's Health Across the Nation (SWAN). Menopause 2022;29(12):1357-64. DOI: 10.1097/GME.0000000000002087.
  15. Harlow SD, Burnett-Bowie SM, Greendale GA, et al. Disparities in reproductive aging and midlife health between Black and White women: the Study of Women's Health Across the Nation (SWAN). Womens Midlife Health 2022;8:3. DOI: 10.1186/s40695-022-00073-y.
  16. LaMonte MJ, Manson JE, Anderson GL, et al. Contributions of the Women's Health Initiative to cardiovascular research: JACC state-of-the-art review. J Am Coll Cardiol 2022;80(3):256-75. DOI: 10.1016/j.jacc.2022.05.016.
  17. Miller VM, Taylor HS, Naftolin F, et al. Lessons from KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric 2021;24(2):139-45. DOI: 10.1080/13697137.2020.1804545.
  18. Chlebowski RT, Barrington W, Aragaki AK, et al. Estrogen alone and health outcomes in Black women by African ancestry: a secondary analysis of a randomized controlled trial. Menopause 2017;24(2):133-41. DOI: 10.1097/GME.0000000000000733.
  19. Owen CM, Pal L, Mumford SL, et al. Effects of hormones on skin wrinkles and rigidity vary by race/ethnicity: four-year follow-up from the ancillary skin study of the Kronos Early Estrogen Prevention Study. Fertil Steril 2016;106(5):1170-5. DOI: 10.1016/j.fertnstert.2016.06.023.
  20. Zouboulis CC, Blume-Peytavi U, Kosmadaki M, et al. Skin, hair and beyond: the impact of menopause. Climacteric 2022;25(5):434-42. DOI: 10.1080/13697137.2022.2050206.
  21. Pivazyan L, Avetisyan J, Loshkareva M, Abdurakhmanova A. Skin rejuvenation in women using menopausal hormone therapy: a systematic review and meta-analysis. J Menopausal Med 2023;29(3):97-111. DOI: 10.6118/jmm.22042.
  22. Lephart ED, Naftolin F. Menopause and the skin: old favorites and new innovations in cosmeceuticals for estrogen-deficient skin. Dermatol Ther (Heidelb) 2021;11(1):53-69. DOI: 10.1007/s13555-020-00468-7.
  23. Roster K, Fleshner L, Karatas TB, et al. Menopause and common dermatoses: a systematic review. Am J Clin Dermatol 2025;27(1):67-84. DOI: 10.1007/s40257-025-00994-0.
  24. Khunger N, Mehrotra K. Menopausal acne: challenges and solutions. Int J Womens Health 2019;11:555-67. DOI: 10.2147/IJWH.S174292.
  25. DeGiovanni C. Navigating melasma: a guide for women of colour and menopausal skin. British Skin Foundation, 2024. (https://www.britishskinfoundation.org.uk/resources/navigating-melasma-a-guide-for-women-of-colour-and-menopausal-skin).
  26. Torres AE, Awosika O, Maghfour J, Taylor S, Lim HW. Practical guide to tinted sunscreens. J Am Acad Dermatol 2022;87(3):656-7. DOI: 10.1016/j.jaad.2021.12.040.
  27. Grimes PE, Paturi J, Chen Y, et al. Photoprotection efficacy of sun protection factor and iron oxide formulations in diverse skin with melasma and photodamage. J Drugs Dermatol 2025;24(7):662-7. DOI: 10.36849/JDD.9240.
  28. Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol 2010;3(7):20-31. PMID: 20725554.
  29. Schmidt JB, Binder M, Demschik G, Bieglmayer C, Reiner A. Treatment of skin aging with topical estrogens. Int J Dermatol 1996;35(9):669-74. DOI: 10.1111/j.1365-4362.1996.tb03701.x.
  30. Campbell C. Estrogen face cream for anti-aging: what San Francisco patients should know about safety and endometrial risk. Caren Campbell MD, 2024. (https://www.carencampbellmd.com/blogs/news/estrogen-face-cream-for-anti-aging-what-san-francisco-patients-should-know-about-safety-endometrial-risk).
  31. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA 2017;318(10):927-38. DOI: 10.1001/jama.2017.11217.